From radiolabeling to receptor quantification: preclinical assessment of [(99m)Tc]Tc-carvedilol as a cardiac β-adrenoceptor probe

从放射性标记到受体定量:[(99m)Tc]Tc-卡维地洛作为心脏β-肾上腺素受体探针的临床前评估

阅读:1

Abstract

INTRODUCTION: Accurate cardiac adrenoceptor assessment is crucial for managing cardiovascular diseases. This study introduces a novel radiotracer, technetium-99m-labeled carvedilol ([(99m)Tc]Tc-carvedilol), which advances non-invasive cardiac receptor evaluation by improving traceability and myocardial tissue selectivity. Aimed at strengthening diagnostic precision, it optimizes a selective radioligand for quantifying cardiac adrenergic receptor sites. METHODS: [(99m)Tc]Tc-carvedilol was synthesized via direct radiolabeling with technetium-99m, key parameters were optimized to maximize radiolabeling efficiency and ensure a reliable and reproducible [(99m)Tc]Tc-carvedilol complex. Biodistribution was rigorously evaluated in vitro and in vivo, emphasizing cardiac uptake, receptor occupancy, biodistribution, and clearance kinetics. Comparative analysis with [(131)I]iodocarvedilol and (99m)Tc-sestamibi provided insights into advancements in detection efficiency and translational potential. RESULTS: [(99m)Tc]Tc-carvedilol showed a radiolabeling efficiency of 96.5% ± 2.87%, with serum stability >92% at 24 h. Biodistribution studies in Swiss Albino mice (24 mice, aged 10-12 weeks, weighing 25 ± 3 g) revealed peak cardiac uptake (27.533% ± 0.931% injected dose per Gram of tissue (ID/g) within 15 min post-injection, alongside efficient blood clearance and minimal non-target tissue uptake (5.972% ± 0.131% ID/g organ) by 120 min. Docking analysis confirmed robust β(1)-adrenoceptors (-9.2 kcal/mol) via hydrogen bonds and hydrophobic and electrostatic interactions. Compared to [(131)I]iodocarvedilol and (99m)Tc-sestamibi [(99m)Tc]Tc-carvedilol exhibited superior stability, targeting accuracy, and pharmacokinetics. DISCUSSION: The enhanced selective cardiac uptake and favorable pharmacokinetics of [(99m)Tc]Tc-carvedilol position it as a promising agent for non-invasive cardiac receptor mapping, with the potential to improve diagnostic accuracy and specificity. Further clinical validation is essential to confirm its efficacy in detecting and evaluating cardiac pathologies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。